An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2
developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary
study (XPF-009-301).